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Abstract
Background and Aims
Proton pump inhibitors (PPIs) have been associated with adverse clinical outcomes
amongst clopidogrel users after an acute coronary syndrome. Recent pre-clinical results
suggest that this risk might extend to subjects without any prior history of cardiovascular dis-
ease. We explore this potential risk in the general population via data-mining approaches.
Methods
Using a novel approach for mining clinical data for pharmacovigilance, we queried over 16
million clinical documents on 2.9 million individuals to examine whether PPI usage was as-
sociated with cardiovascular risk in the general population.
Results
In multiple data sources, we found gastroesophageal reflux disease (GERD) patients ex-
posed to PPIs to have a 1.16 fold increased association (95% CI 1.09–1.24) with myocardial
infarction (MI). Survival analysis in a prospective cohort found a two-fold (HR = 2.00; 95%
CI 1.07–3.78; P = 0.031) increase in association with cardiovascular mortality. We found
that this association exists regardless of clopidogrel use. We also found that H2 blockers,
an alternate treatment for GERD, were not associated with increased cardiovascular risk;
had they been in place, such pharmacovigilance algorithms could have flagged this risk as
early as the year 2000.
Conclusions
Consistent with our pre-clinical findings that PPIs may adversely impact vascular function,
our data-mining study supports the association of PPI exposure with risk for MI in the
PLOSONE | DOI:10.1371/journal.pone.0124653 June 10, 2015 1 / 16
OPEN ACCESS
Citation: Shah NH, LePendu P, Bauer-Mehren A,
Ghebremariam YT, Iyer SV, Marcus J, et al. (2015)
Proton Pump Inhibitor Usage and the Risk of
Myocardial Infarction in the General Population. PLoS
ONE 10(6): e0124653. doi:10.1371/journal.
pone.0124653
Academic Editor: Yiru Guo, University of Louisville,
UNITED STATES
Received: January 9, 2015
Accepted: March 17, 2015
Published: June 10, 2015
Copyright: © 2015 Shah et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The data in
consideration are electronic medical records of
patients at Stanford university, and medical records of
a subset of patients at Practice Fusion. Current
patient privacy rules do not allow sharing of electronic
medical records without an explicit IRB review. The
authors can make access to de-identified data
available after appropriate approvals. Contact: Nigam
Shah, nigam@stanford.edu.
Funding: PL, ABM, NHS and SVI acknowledge
support from the NIH grant U54HG004028 for the
National Center for Biomedical Ontology, NLM grant
general population. These data provide an example of how a combination of experimental
studies and data-mining approaches can be applied to prioritize drug safety signals for
further investigation.
Introduction
The primary indication for proton pump inhibitors (PPIs) is gastroesophageal reflux disease
(GERD). Each year, it is estimated that over 113 million PPI prescriptions are filled globally.
This, together with over-the-counter use, accounts for over $13 billion sales worldwide [1] [2].
In the US alone, about 21 million people used one or more prescription PPIs in 2009, making it
the third highest seller in the country [3][2]. The availability of PPIs over-the-counter is partic-
ularly more worrisome due to the absence of medical supervision [1].
For individuals with a history of acute coronary syndrome (ACS), PPIs appear to reduce the
efficacy of clopidogrel, an antiplatelet agent used to reduce the risk for subsequent ischemic
events [4]. There are several competing theories about whether (and how) PPIs enhance the
risk of major adverse cardiovascular events (MACE) amongst individuals with a history of
ACS.[5–10] A leading hypothesis is that PPIs compete for and inhibit the clopidogrel-activat-
ing hepatic isoenzyme, CYP2C19, thereby interfering with clopidogrel’s capacity to prevent
clot formation in subjects at risk for coronary thrombosis and myocardial infarction (MI).[11]
However, some studies have associated PPI usage with adverse clinical outcomes in high-
risk cardiovascular populations, independently of clopidogrel use.[7] For example, a reduction
in therapeutic benefit has been reported in ACS patients treated with the antiplatelet agents as-
pirin and ticagrelor, neither of which requires activation by CYP2C19. [12, 13] While it is pos-
sible that PPIs may reduce the absorption of these drugs (a controversial hypothesis given that
PPIs have been shown not to diminish the anti-platelet aggregation properties of aspirin [14,
15]), it is important to note that a similar reduction in gastric pH is achieved with H2 blockers
(H2Bs), which have been shown not to increase cardiovascular risk [12, 13].
An alternative explanation is that the observed risk of PPIs is due to some unknown mecha-
nistic pathway [12], and that this pathway may not be restricted to vasculopathic patients. In
this regard, we recently reported that PPIs inhibit the enzymatic activity of dimethylarginine
dimethylaminohydrolase (DDAH), [16] which is responsible for 80% of the clearance of asym-
metric dimethylarginine (ADMA)—an endogenous molecule known to inhibit the enzymatic
activity of nitric oxide synthase (NOS).[17] An impairment in endothelial NOS (eNOS) is well-
known to increase vascular resistance, and promote inflammation and thrombosis.[18] ADMA
is a potent disease marker and independent predictor of MACE in prior observational studies.
[19–24] Our recent pre-clinical studies found that PPIs increase ADMA levels in human endo-
thelial cells and in mice by about 20–30%.[16]
To date, we are aware of only one study which has examined the cardiovascular risk associa-
tion of PPIs outside of high-risk cohorts [25]. This is a concern given our translational data,
which suggests that the risk of these drugs may apply to subjects not taking antiplatelet agents,
and those without any vascular disease. Therefore, we employed a novel and recently validated
[26, 27] data-mining approach for pharmacovigilance on multiple electronic medical record
datasets as well as examined a prospectively followed clinical cohort [28, 29], to explore the
possibility that PPIs may be associated with cardiovascular risk in the general US population.
PPIs Associated with MI
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Methods
The data mining studies were deemed by the Stanford IRB not to involve human patients. The
Stanford GenePAD study was approved by the Stanford Human Subjects Research Institution-
al Review Board and was conducted under the guidelines of the Declaration of Helsinki, with
written informed consent was obtained from all participants.
Data sources
We used two data sources for our data mining analysis—a primary source from Stanford and a
secondary source from Practice Fusion, Inc—and one prospective source for the
survival analysis.
At Stanford University, all clinical notes (both inpatient and outpatient) have been tran-
scribed and recorded electronically since 1994. These data are warehoused for research use in
the Stanford Translational Research Integrated Database Environment (STRIDE).[30] STRIDE
contains data from 1.8 million patients, 19 million encounters, 35 million coded International
Classification of Disease (ICD-9) diagnoses, and a combination of pathology, radiology, and
transcription reports totaling over 11 million unstructured clinical notes.
Practice Fusion, Inc. (PF) provides a free, web-based Electronic Health Record (HER) sys-
tem for clinicians. The company’s users are primarily small practices providing outpatient
care. Roughly, half of these practices specialize in primary care, with 29% of users from the
West, 13% from the Southwest, 14% fromMidwest, 27% from the Southeast, and 18% from the
Northeast. The de-identified subset of PF data used in our analysis contained data on 1.1 mil-
lion patients, 5.5 million coded diagnoses, 6.8 million prescriptions, and 5.5 million unstruc-
tured clinical notes dating back to 2007.
Additionally, we examined the association of PPI use at enrollment with subsequent cardio-
vascular mortality in the GenePAD (the Genetic Determinants of Peripheral Arterial Disease)
[28, 29] study. The GenePAD cohort is comprised of individuals who underwent an elective,
non-emergent coronary angiogram for angina, shortness of breath or an abnormal stress test at
Stanford University or Mount Sinai Medical Centers. Cardiovascular mortality was defined as
that from myocardial infarction, cardiac arrest, stroke, heart failure or aneurysm rupture. Car-
diovascular outcomes were assessed through medical record review and confirmed by contact-
ing the patient or next of kin directly. This form of dual follow-up was specifically
implemented to limit detection bias from differential frequencies in physician contact between
groups. Finally, all deaths were confirmed and cross-referenced to the SSDI to minimize detec-
tion bias. The study cohort commenced in 2004 and included 1,503 individuals.
Data-mining pipeline for pharmacovigilance
We used a previously validated data-mining pipeline for pharmacovigilance using clinical data
[26] [31] to screen whether the exposure to proton pump inhibitors is associated with an ele-
vated risk of myocardial infarction in the general population. Note that such a data-mining
procedure is not the same as performing an epidemiological study. The difference between per-
forming an epidemiological study and a data-mining study is categorically described in [32].
Briefly, data-mining approaches focus on learning a valid function f(x)—which is modeled as
an algorithm that operates on variables (x) to predict the responses (y). The linking function f
(x) in a data-mining study can be a regression, but cannot, and should not, be interpreted as a
causal regression model which is typically the goal of an epidemiological study.
The validation of data-mining approaches is performed by measuring predictive accuracy
and is widely adopted in computer science [33], and increasingly in economics [34]. Our data-
mining approach, which aims to minimize false positives, has 97.5% specificity and 39%
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sensitivity in discerning a true association as determined using a gold standard set of 28 true
positive and 165 negative associations spanning 78 drugs and 12 different outcomes [35]. This
performance provides an accuracy of 89% and has a positive predictive value of 81% if we test
an equal number of true and false associations. We summarize the approach briefly, and fur-
ther details are provided in LePendu et al [26].
The pipeline extracted positive-present mentions of drug, disease, device, and procedure
concepts from all clinical notes, accounting for negation and other contexts, into a patient–fea-
ture matrix that we analyzed. Drug terms were normalized to active ingredients using RxNorm,
and classified according to the Anatomical Therapeutical Chemical classification system. For
example, “Prilosec” and “omeprazole” were treated equally; while omeprazole, rabeprazole,
and so on were grouped together as the class of PPIs. Disease terms were normalized and ag-
gregated according to the hierarchical relationships from the Unified Medical Language System
Metathesaurus and BioPortal. Finally, we aligned records temporally based on the time at
which each note was recorded and only kept positive-present–first mentions. The matrix (for
STRIDE) comprises nearly a trillion pieces of data—roughly, 1.8 million patients as rows, thou-
sands of clinical concepts as columns, with time as the third dimension (see Fig 5 in LePendu
et al [26]).
Patient population and outcome definition. GERD is the primary indication for PPIs, so
we used the presence of this indication to define the baseline population in our pipeline. We ex-
cluded all patients under the age of 18 at their first GERD mention. We defined GERD by In-
ternational Classification of Diseases, Ninth Revision (ICD-9) codes for esophageal reflux
(530.81) and heartburn (787.1), and the UMLS code for gastroesophageal reflux disease
(C0017168). The main outcome of interest, MI, was defined by acute myocardial infarction
(ICD-9 code 410), and more than 18 different UMLS codes including myocardial infarction
(C0027051) and silent myocardial infarction (C0340324). See S1 Table for full definitions.
Study groups and study periods. The study period included all data from 1994 through
2011 in STRIDE and 2007 through 2012 in PF. We defined two study groups within the GERD
baseline population in this period. The primary study group was the subset defined by patients
taking PPIs, including a sub-group of those patients who were not on clopidogrel. We consid-
ered six PPIs (omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and dexlan-
soprazole) individually and as a class. We excluded dexlansoprazole from individual analysis
because of insufficient exposure (<100 patients). As an alternative treatment for GERD we ex-
amined H2 blockers (H2Bs—cimetidine, famotidine, nizatidine, and ranitidine) as a separate
association test.
Association estimation. The summary of the data-mining pipeline shown in the S1 Fig
outlines the decisions used in the data-mining pipeline to populate a contingency table for each
of the associations tested. Each patient was counted according to the temporal ordering of con-
cepts in the patient–feature matrix as described in LePendu et al [26]. For example, a mention
of PPI use after a GERD indication would be counted as an exposure. A subsequent mention of
MI counts as an associated outcome. Our data-mining method works based on “beforeness” of
treatments and events and given the uncertainty the exact times of treatment and the messy
EMR data used, we follow a two-step process for detecting drug safety signals (details in meth-
ods of LePendu et al) [26]. First we compute a raw association, followed by adjustment which
involves matching on age, gender, race, length of observation, and, as proxies for health status,
the number of unique drug and disease concepts mentioned in the full record. The first step is
useful for flagging putative signals, and the second step in reducing false alarms. As in prior
work, we attempted to match up to 5 controls. In cases where there are not enough controls to
draw from, we tried either 1:3 or finally 1:1 matching (Table 1). The balance of variables before
and after matching for the PPI study group is shown in Table 2. The balance of variables for
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the H2Bs study group is shown in Table 3. Note that the purpose of this matching is to reuse our
validated two-step data-mining approach from LePendu et al [26] and not emulate an epidemio-
logical study from the EMR data. In each of the two steps, we compute the odds-ratio as well as
confidence interval (CI) using logistic regression and use a significance cutoff of p-value< 0.01.
Survival analysis in a prospective cohort
For all survival analyses in the GenePAD cohort, the follow-up time was defined as the period
between the enrollment interview and the last confirmed follow-up or date of death. Cox pro-
portional hazards models were used to calculate adjusted and unadjusted hazard ratios (HR)
and 95% CI for the association of PPI use with cardiovascular mortality. Adjusted models in-
cluded age, gender, race, total cholesterol, high-density lipoprotein cholesterol, systolic blood
pressure, use of anti-hypertension medications, and lifetime pack-years.
Results
Patients receiving clopidogrel (or other anti-platelet agents) post ACS have been extensively
studied previously [5, 7–10, 12, 13, 15, 36]. In our study the primary population of interest is
patients with GERD. We find that the class-level association of PPIs with MI in patients treated
for GERD exists across two independent datasets and is independent of clopidogrel use and
high-risk age groups. By comparison, we find no association with MI in GERD patients treated
with H2Bs in the same dataset. The results from the data-mining effort are concordant with
our analysis in a prospectively followed cohort from the GenePAD [28, 29] study, showing in-
creased cardiovascular mortality associated with PPI use and no such increase associated with
H2B use.
Table 1. Study group populations for the STRIDE dataset, including 5:1 propensity matching.
Before Matching After Matching
Study Group and Subgroups N (GERD = 93,149) Exposed Control Match Ratio Exposed Control
Age > = 18 ‡ 70,477
PPI * 32,363 38,114 1:1 32,363 32,099
(–) clopidogrel † 30,454 35,856 1:1 30,454 30,275
Age < = 45 *‡ 9,595 12,846 1:1 9,595 9,568
Age < = 55 *‡ 16,662 21,016 1:1 16,662 16,546
H2 blocker * 12,796 57,681 1:3 12,796 38,388
omeprazole * 8,921 28,498 1:3 8,921 26,763
esomeprazole * 2,907 27,049 1:5 2,907 14,535
pantoprazole * 4,450 28,001 1:5 4,450 22,250
rabeprazole * 2,473 26,972 1:5 2,473 12,365
lansoprazole * 4,005 27,596 1:5 4,005 20,025
There are 93,149 patients with gastroesophageal reflux disease (GERD), of which 70,477 are at least 18 years old. In all study groups other than the one
in which clopidogrel patients are excluded, the populations are matched (and balanced) based on clopidogrel use and other covariates such as age,
gender, race, length of observation, number of unique drugs mentioned in the record, and validated proxies of health status (based on the number of
unique disease concepts attributed to each patient). The matching process attempts to achieve a ratio of 1:5 (exposure to control), but will settle for 1:3 or
1:1 if there are not enough controls from which to draw.
* balanced for clopidogrel use
† patients on clopidogrel are excluded
‡ patients are restricted by age
doi:10.1371/journal.pone.0124653.t001
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Table 2. Balance of variables for patients on PPIs in the STRIDE dataset.
Variable Before Matching After Matching
Exposed
(N = 32,363)
Unmatched controls
(N = 38,114)
p-value Matched controls
(N = 32,099)
p-
value
Demographics
Age at indication (GERD), mean
(sd)
54.88 (16.65) 53.47 (17.15) <2.22e-
16
54.52 (17.13) 0.005
Gender (male), n (%) 44.31 45.60 0.0006 44.61 0.44
Race, n (%)
Asian 7.93 8.92 < 0.0001 8.33 0.13
Black 2.77 2.84 0.62 2.96 0.15
Other 11.82 11.58 0.33 11.92 0.71
Unknown 27.07 26.52 0.09 25.84 0.0001
White 50.41 50.14 0.49 50.95 0.16
Co-prescription
Clopidogrel, n(%) 5.90 5.93 0.89 6.16 0.16
Other
No. of unique diseases, n (%)
1–28 7.72 12.78 <0.0001 7.30 0.34
29–41 9.45 9.67 0.34 8.87 0.002
42–56 10.16 10.07 0.72 9.98 0.42
57–74 10.44 10.12 0.16 10.27 0.46
75–95 10.26 9.76 0.03 10.28 0.91
96–121 9.93 9.66 0.23 10.35 0.08
122–157 10.47 9.62 0.0001 10.79 0.18
158–207 10.37 9.37 9.9e-06 10.64 0.26
208–294 10.53 9.62 6.3e-05 10.79 0.26
>294 10.67 9.33 3.8e-09 10.73 0.81
No. of unique drugs, n (%)
1–9 5.78 14.23 <0.0001 5.80 0.92
10–15 9.18 10.03 0.0001 9.48 0.16
16–22 11.05 10.48 0.01 10.89 0.50
23–29 9.76 8.92 0.0001 9.51 0.29
30–38 10.93 9.37 8.0e-12 10.66 0.27
39–49 10.74 9.84 0.0001 10.94 0.33
50–64 10.80 9.43 1.7e-09 10.93 0.60
65–86 10.81 8.95 2.2e-16 10.48 0.15
87–123 10.74 9.12 9.5e-13 10.61 0.57
>123 10.21 9.63 0.009 10.70 0.05
Length of observation (days), n
(%)
1–9 8.97 10.92 <0.0001 8.37 0.007
10–102 9.90 10.05 0.52 9.59 0.17
103–364 9.72 10.25 0.02 9.89 0.48
365–816 9.95 10.02 0.77 10.21 0.25
817–1426 9.87 10.11 0.29 10.12 0.21
1427–2156 9.64 10.31 0.003 10.10 0.05
2157–3018 9.77 10.20 0.06 10.27 0.03
3019–3956 10.40 9.66 0.001 10.48 0.76
(Continued)
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Characteristics of the primary clinical dataset
All patients with GERD above the age of 18, representing the general population likely to take a
PPI, comprise the baseline population for our studies. The two study groups include patients
exposed to PPIs, and, for comparison, patients exposed to H2Bs. Controls were selected from
the baseline population using propensity score matching [37] (see Methods).
Our results were replicated across two independent datasets—one from Stanford (~1.8 mil-
lion patients) and a subset of data from Practice Fusion, Inc. (PF) (~1.1 million patients).
Table 1 summarizes the characteristics of the baseline and study populations for the primary
dataset from Stanford, called STRIDE. Similar distributions were seen in the PF dataset. Over-
all, out of all patients in STRIDE, 93,149 have had GERD (of which 70,477 are at least 18 years
old); 22,411 have had a MI; 59,109 have taken at least one H2B; and 16,127 have taken clopido-
grel. The characteristics of each of the study groups are balanced for exposed and unexposed
patients, noting in particular that clopidogrel use is balanced (Tables 2 and 3).
In the baseline population for STRIDE (N = 70,477), 45.9% used at least one PPI (12.7%
omeprazole, 5.7% lansoprazole, 6.3% pantoprazole, 4.1% esomeprazole, 3.5% rabeprazole, and
0.1% dexlansoprazole) and 18.2% used an H2B (Table 1). The mean follow-up time is 2.1 years
in the PPI study group, and 2.5 years in the H2B group. Of all PPI patients, less than 6% used
clopidogrel—highlighting the relatively small size of the well-studied ACS populations com-
pared to the general population of PPI users.
A safety signal for an association with MI
For our data-mining method, a threshold of 1.0 on the lower bound of the 95% confidence in-
terval of the adjusted odds ratios provides 39% sensitivity and 97.5% specificity in signaling an
association—translating to a 3.5% false positive rate and a 61% false negative rate (making it a
conservative test) [26]. Fig 1A shows that PPIs as a class (N = 32,363) are associated with MI
with an adjusted odds ratio (AOR) of 1.16 (95% CI 1.09–1.24). Fig 1B shows the associations
for each PPI individually. The strength of association varies slightly for each PPI, ranging from
AOR 1.08 to 1.34.
H2 blockers signal no association with MI
Given our hypothesis about the mechanism by which PPIs confer the increased risk, H2Bs
(N = 12,796), an alternative treatment for GERD, are not expected to be associated with MI.
Fig 1A confirms a lack of association (AOR 0.93; 95% CI 0.86–1.02).
Table 2. (Continued)
Variable Before Matching After Matching
Exposed
(N = 32,363)
Unmatched controls
(N = 38,114)
p-value Matched controls
(N = 32,099)
p-
value
3957–5084 10.88 9.25 8.4e-13 10.44 0.06
>5084 10.90 9.23 2.6e-13 10.53 0.12
PPI exposure and control groups for patients with gastroesophageal reflux disease (GERD) are balanced across a number of basic covariates.
Importantly, the use of clopidogrel is equally balanced across exposed and control groups. Other variables (no. of unique disease mentions, no. unique
drug mentions, length of observation) are binned according to their distributions. Before matching, PI patients tend to be sicker, have more diseases and
more drugs mentioned in their record. After matching, these variables are balanced.
doi:10.1371/journal.pone.0124653.t002
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Table 3. Balance of variables in patients on H2 blockers in the STRIDE dataset.
Variable Before Matching After Matching
Exposed (N = 12,796) Unmatched controls (N = 57,681) p-value Matched controls (N = 38,388) p-value
Demographics
Age at indication (GERD), mean (sd) 52.90 (16.85) 54.38 (16.95) <2.22e-16 53.19 (16.74) 0.13
Gender (male), n (%) 42.76 45.50 1.38e-08 43.26 0.41
Race, n (%)
Asian 9.27 8.28 0.0003 9.02 0.41
Black 3.41 2.68 2.55e-05 3.19 0.33
Other 11.80 11.67 0.67 11.60 0.61
Unknown 23.43 27.51 < 2.22e-16 24.24 0.12
White 52.09 49.86 4.70e-06 51.95 0.82
Co-prescriptions
Clopidogrel, n(%) 6.99 5.67 7.1e-08 6.75 0.45
Other
No. of unique diseases, n (%)
1–28 6.05 11.44 < 0.0001 6.12 0.79
29–41 6.71 10.21 < 2.22e-16 6.83 0.68
42–56 7.92 10.60 < 2.22e-16 8.11 0.55
57–74 8.79 10.59 1.55e-10 9.22 0.21
75–95 9.14 10.17 0.0003 9.58 0.22
96–121 9.40 9.87 0.10 10.07 0.07
122–157 10.90 9.81 0.0003 11.88 0.01
158–207 11.46 9.47 9.59e-11 12.25 0.05
208–294 13.15 9.34 < 2.22e-16 13.19 0.92
>294 16.48 8.50 < 2.22e-16 12.75 < 2.22e-16
No. of unique drugs, n (%)
1–9 4.01 11.83 < 0.0001 4.02 0.98
10–15 6.84 10.26 < 2.22e-16 6.78 0.85
16–22 8.33 11.25 < 2.22e-16 8.46 0.67
23–29 8.01 9.59 4.58e-09 8.24 0.48
30–38 9.91 10.12 0.47 10.68 0.04
39–49 10.37 10.20 0.58 11.18 0.03
50–64 10.90 9.87 0.0006 12.10 0.001
65–86 11.61 9.40 9.31e-13 12.63 0.008
87–123 13.29 9.10 < 2.22e-16 13.32 0.94
>123 16.73 8.38 < 2.22e-16 12.59 < 2.22e-16
Length of observation (days), n (%)
1–9 6.56 10.81 < 0.0001 6.56 1
10–102 7.36 10.56 < 2.22e-16 7.40 0.90
103–364 8.45 10.35 7.87e-12 8.95 0.15
365–816 9.71 10.04 0.25 9.95 0.51
817–1426 9.97 10.01 0.91 10.24 0.47
1427–2156 10.44 9.90 0.07 10.61 0.65
2157–3018 10.68 9.84 0.005 10.70 0.97
3019–3956 11.80 9.60 1.17e-12 11.70 0.39
3957–5084 11.99 9.56 7.55e-15 11.69 0.46
>5084 13.04 9.33 < 2.22e-16 12.20 0.04
PPI exposure and control groups for patients with gastroesophageal reflux disease (GERD) are balanced across a number of basic covariates.
Importantly, the use of clopidogrel is equally balanced across exposed and control groups. Continuous variables (no. of unique disease mentions, no.
unique drug mentions, length of observation) are binned according to their distributions. Before matching, H2 blocker patients tend to be sicker, have more
diseases and more drugs mentioned in their record. After matching, these variables are mostly balanced.
doi:10.1371/journal.pone.0124653.t003
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Associations are independent of clopidogrel use and age
Patients who take clopidogrel have often experienced a prior MI, and are likely to experience a
second event. This population has been extensively studied [5, 7–10, 12, 15, 36]. A small frac-
tion (~6%) of the PPI and H2B study groups are also on clopidogrel, which we examine sepa-
rately for completeness. However, a known limitation of our data-mining methods, which
focuses on first mentions, is the inability to pinpoint repeat occurrences of events [26], making
it difficult to examine the clopidogrel treated group for a repeat coronary event. We addressed
this by excluding patients with clopidogrel exposure.
Fig 1C, shows that the associations persist after excluding patients on clopidogrel and the as-
sociation persists across age groups. Fig 1C shows that in patients not using clopidogrel
(N = 30,275), the adjusted odds ratio does not differ markedly from general PPI use (AOR
1.14; 95% CI 1.06–1.24).
Fig 1. PPI use is associated with an increased risk for MI, regardless of age or clopidogrel use. No association is identified for H2 Blocker use: In the
fig, the dotted red line represents the reference point indicating no elevated risk for myocardial infarction (MI). The odds ratio and 95% confidence interval for
each exposure are indicated by a blue dot and blue line, respectively, which are also represented numerically to the right of each fig. The size of the dot is
proportional to the exposure size of each group (see Table 1). Fig A, derived from STRIDE (N = 70,477), shows that PPIs have a class-level effect for MI in
the general population of patients with GERD. By comparison, H2 blockers, an alternate treatment, have no association. Fig B breaks down the associations
for each PPI individually. Figs C and D use stratification to show that the signals are corroborated in two independent datasets (STRIDE and Practice Fusion)
and are robust in important subgroups. Fig C shows that, for the STRIDE dataset, when patients on clopidogrel are excluded, the associations are
unchanged. Also, in lower-risk age groups for MI, the associations are still present. Similar trends are seen in these subgroups in the Practice Fusion (PF)
dataset (N = 227,438) shown in Fig D.
doi:10.1371/journal.pone.0124653.g001
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The results suggest that associations with MI are unlikely to be due to an interaction with
clopidogrel, a surrogate for prior ACS history, which by itself would increase the likelihood of a
second MI. In terms of risks related to age, Fig 1C also shows that the risks extend to individu-
als younger than 55 years old (N = 16,662), who are not a high-risk age group for MI. The
mean age in the younger sub-group is 41.7, versus 54.5 in the general population, as shown in
Table 2.
Corroboration in an independent nationwide dataset
Fig 1D shows a PPI class effect for an association with MI from an independent dataset. The
PF dataset has a much larger and more heterogeneous set of GERD patients in the baseline
population (N = 227,438) given the source of the data (see Table 4). The duration of coverage
is shorter (2007 through 2012), with more patients entering the dataset only in recent years. As
a result, balancing length of observation is difficult and our estimates of the method’s accuracy
(described in the methods section) might not generalize. However, the results showed similar
trends in the PF dataset data (AOR 1.19; 95% CI 1.09–1.30; Fig 2C and 2D) as were seen in
STRIDE.
Survival analysis shows an association with cardiovascular mortality
In a separate analysis on the prospectively followed Genetic Determinants of Peripheral Arteri-
al Disease [28, 29] (GenePAD) cohort—independent of our text-mining approach—there were
58 cardiovascular mortalities during a median follow-up period of 5.2 years (interquartile
range, 4.1–6.3). Using a Cox proportional hazard model, an unadjusted analysis showed a
122% increased cardiovascular mortality risk among PPI users as measured by the hazard ratio
(HR = 2.22; 95% CI 1.19–4.16; P = 0.013). This association persisted in the fully adjusted
Table 4. Study group populations for the PF dataset.
Before Matching After Matching
Study Group and Subgroups N (GERD) Exposed Control Match Ratio Exposed Control
Age > = 18 ‡ 227,438
PPI 74,516 152,922 1:2 72,497 152,922
(–) clopidogrel † 72,399 150,269 1:2 71,234 150,268
Age < = 45 ‡ 17,508 29,454 1:2 13,287 29,453
Age < = 55 ‡ 32,154 57,474 1:2 26,434 57,474
omeprazole 43,103 144,582 1:3 43,103 134,339
esomeprazole 8,078 129,049 1:5 8,078 44,521
pantoprazole 3,680 129,000 1:5 3,680 21,027
rabeprazole 998 128,570 1:5 998 5,808
lansoprazole 5,493 130,453 1:5 5,493 29,531
There are 227,438 patients with gastroesophageal reflux disease (GERD) who are at least 18 years old in this confirmation cohort. In all study groups
other than the one in which clopidogrel patients are excluded, the populations are matched based on clopidogrel use and other covariates such as age,
gender, race, length of observation, and number of unique drugs mentioned in the record as well as the number of unique disease concepts (as proxies
for health status). The matching process attempts to achieve a ratio of 1:5 (exposure to control), but will settle for 1:3, 1:2, or 1:1 if there are not enough
controls from which to draw. The length of observation in the PF dataset makes balancing variables difficult, so confounding cannot be entirely ruled out
even after matching.
† patients on clopidogrel are excluded
‡ patients are restricted by age
doi:10.1371/journal.pone.0124653.t004
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model (HR = 2.00; 95% CI 1.07–3.78; P = 0.031), which controlled for several cardiovascular
comorbidities. Fig 2 shows a Kaplan–Meier curve representing the survival function from car-
diovascular mortality for patients on PPIs versus controls. As with the text-mining analysis, no
association was seen with H2Bs in either unadjusted (HR = 1.05; 95% CI 0.15–7.59; P = 0.962)
or adjusted (HR = 1.00; 95% CI 0.14–7.26; P = 0.996) analyses.
Associations are detectable as early as the year 2000
The cumulative risk and exposure plot for lansoprazol shown in Fig 3 is based on the raw asso-
ciation estimates, which help to flag signals for early detection and monitoring as described in
previous work.[26] Based on this plot, lansoprazole would have been flagged for monitoring in
the year 2000 if we had such a data-mining system in place. As exposure data accumulates, the
confidence intervals converge (note the narrowing 95% confidence intervals). Plots for the
other PPIs are shown in the S2 Fig.
Discussion
Our results demonstrate that PPIs appear to be associated with elevated risk of MI in the gener-
al population; and H2 blockers show no such association. The associations are independent of
clopidogrel use or age-related risks and are seen in two large independent datasets and a pro-
spective cohort. In particular, the association is seen outside of the high-risk populations previ-
ously examined, such as the elderly [38] or patients with ACS [2].
Fig 2. Survival plot from the prospectively followed GenePAD study confirms that PPI use is associated adverse outcome. The Kaplan–Meier
curves in the fig show the survival probability from cardiovascular mortality according to PPI usage over an 8 years follow-up period in the ongoing Genetic
Determinants of Peripheral Artery Disease (GenePAD) study. PPI usage is associated with a 2.22 fold (CI 1.19–4.16) increased risk of cardiovascular
mortality, relative to controls in unadjusted Cox proportional hazards models.
doi:10.1371/journal.pone.0124653.g002
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Our results are consistent with findings in the extensively-studied cohort of subjects with
coronary artery disease (CAD) [5, 7, 12, 36], where PPIs have repeatedly been associated with
adverse outcomes amongst patients receiving clopidogrel. [15] While two prospective studies
in the post-ACS population failed to detect an association between PPI use and an increased
risk of cardiovascular death, MI, or stroke [9, 10], the authors acknowledged that their results
do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.
[10] In fact both studies included patients at a higher risk of MI than the general population,
which may eclipse any potential harm conferred by PPIs due to competing risks. [38, 39] Based
on the concern that PPIs could reduce the metabolism of clopidogrel to its active form, the
FDA issued a warning about this possible drug-drug interaction in 2009 [40].
The current study suggests that the risk of PPIs may extend beyond previously studied high
risk individuals. These findings confirm and extend the findings of Shih and colleagues, which
suggested that PPIs were associated with short term cardiovascular harm amongst Taiwanese
individuals [25], and are consistent with studies which have shown that PPIs may diminish the
cardioprotective effects of drugs that do not depend on CYP2C19 activation, such as ticagrelor
[7, 12, 13]. While it has been argued that this phenomenon might result from PPI-induced
changes in drug absorption, we view this as a less likely possibility given that H2 blockers in-
duce a similar reduction in gastric pH—without consistently increasing cardiovascular risk, as
observed in each of three datasets studied here.[12] Other potential explanations for the ob-
served association are that PPIs might impair cardiovascular hemodynamics or promote nutri-
tional deficiencies. For example, PPIs have been reported to induce negative inotropic effects
on myocardial tissue ex vivo, [41, 42] and to potentially increase the cardiovascular risk factor,
homocysteine, by impairing the absorption of vitamin B12. [43, 44] However, population-
based cohort studies have demonstrated a lack of excess mortality in patients with both
Fig 3. Cumulative risk and exposure plots reveal that pharmacovigilance algorithms could have flagged lansoprazole for monitoring as early as
the year 2000. The x-axis is calendar year; the y-axis on the left is the unadjusted odds ratio; the y-axis on the right is the number of patients exposed. The
solid red line is the point estimate of the odds ratio. The dotted red lines are the confidence intervals. The blue line is the number of patients exposed. Vertical
lines mark the earliest detected signal—the year when the lower bound on the 95% confidence interval rises above 1.0. Signal detection algorithms on
clinical notes would have flagged lansoprazole for monitoring as early as the year 2000.
doi:10.1371/journal.pone.0124653.g003
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ischaemic and non-ischaemic heart failure prescribed PPIs, [45] and consensus opinion is that
PPIs are unlikely to cause a clinically relevant reduction in B12 levels in people on a normal
diet, with otherwise normal gastrointestinal function [43].
Our observation that PPI usage is associated with harm in the general population—includ-
ing the young and those taking no antiplatelet agent—suggests that PPIs may promote risk via
an unknown mechanism that does not directly involve platelet aggregation. Accordingly, our
recent molecular, cellular, physiological, and in vivo data [16] demonstrating that PPIs inhibit
DDAH activity may explain how PPIs promote cardiovascular risk, and do so even in individu-
als not taking clopidogrel. DDAH, an enzyme necessary for cardiovascular health, metabolizes
ADMA, an endogenous and competitive inhibitor of nitric oxide synthase (NOS).[46] In-
creases in plasma ADMA levels of as little as 10% are associated with increased risk of major
adverse cardiovascular events.[19–24] We previously confirmed that PPIs inhibit purified
DDAH enzyme using orthogonal assays. As a result, PPIs increased intracellular ADMA in cul-
tured human endothelial cells by approximately 30%, increased serum ADMA levels in mice
by approximately 20%, impaired endothelium-dependent vasodilation of isolated mouse aor-
tae, and reduced the generation of nitric oxide by human saphenous vein segments obtained at
the time of coronary artery bypass.[16] Taken together, these results provide a plausible mech-
anism for how PPI usage can manifest with dysregulation of vascular NOS, and therefore ex-
plain the association with increased risk of MI in the general population.
Our study is subject to several limitations. Most importantly, these observational data may
be subject to confounding in multiple ways, and it is possible that PPI usage is merely a marker
of a sicker patient population [13]. For example, we were unable to control for factors such as
obesity and insulin resistance, and it may be that in some individuals PPIs were prescribed for
angina that was misidentified as acid reflux. However, the observation that alternative heart-
burn medications such as H2 blockers were not associated with harm lends support to the con-
cept that PPIs may specifically promote risk. Although our data-mining pipeline has high
specificity and was validated to have high accuracy (89%), there is still a possibility that the as-
sociation detected is a false positive. We also cannot account for over-the-counter PPI usage,
or differences by drug dosage. We attempt to partially offset these limitations by including rep-
lication data from multiple sources (the community-based PF dataset, the tertiary-care Stan-
ford dataset, and the prospective GenePAD study), and by adjusting for several cardiovascular
covariates in the survival analysis. Nonetheless, we recognize that these findings are hypothesis
generating, and a prospective randomized study in the general population (inclusive of both
lean and obese individuals) is required before changing clinical practice. However, the number
of subjects needed to detect harm among PPI users for MI is considerable, projected to be
about 4,000 by Shih et al [25].
In conclusion, we use a novel analytical pipeline to associate PPI usage with risk of MI in
the general population, independent of clopidogrel use. These findings, in conjunction with the
preclinical results, necessitate additional investigation. Our work also puts forth an example
use case of the learning health system on how multiple clinical data sources can be examined
via data-mining to identify drug safety signals for further investigation. [47, 48]
Supporting Information
S1 Table. Indication, Drug, and Event definitions. For each clinical concept, a set of seed
concept unique identifiers (CUIs) is used to generate a list of strings used to search through the
clinical text.
(PDF)
PPIs Associated with MI
PLOS ONE | DOI:10.1371/journal.pone.0124653 June 10, 2015 13 / 16
S1 Fig. Summary of the data-mining pipeline. To construct a contingency table, patients with
gastroesophageal reflux disease (GERD) who were over 18 years old at the time of indication
were identified and used to form the baseline population. The drugs of interest were PPIs, clo-
pidogrel, and H2 blockers. The outcome was MI. The temporal ordering of the drug and out-
come determined into which cell of a 2x2 contingency table each patient would be counted.
(PDF)
S2 Fig. Cumulative risk and exposure plots for PPI–MI. Reveal that pharmacovigilance algo-
rithms could have flagged omeprazole and lansoprazole for monitoring as early as the year
2000.
(PDF)
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